David A. Siegel Spring Works Therapeutics, Inc. Transaction History

Two Sigma Advisers, LP

$43.8 Billion
Q2 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Spring Works Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 42,000 shares of SWTX stock, worth $1.39 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

42,000

Holding current value

$1.39 Million

% of portfolio

0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$36.06 - $47.62 $1.51 Million - $2 Million	42,000 New	42,000 $1.58 Million
Q3 2023 Nov 14, 2023	SELL	$23.12 - $31.38 $397,664 - $539,736	-17,200 Reduced 58.11%	12,400 $286,000
Q2 2023 Aug 14, 2023	SELL	$23.15 - $32.71 $1.56 Million - $2.2 Million	-67,200 Reduced 69.42%	29,600 $776,000
Q1 2023 May 15, 2023	SELL	$24.97 - $34.05 $1.45 Million - $1.97 Million	-57,900 Reduced 37.43%	96,800 $2.49 Million
Q4 2022 Feb 14, 2023	BUY	$21.73 - $28.72 $36,941 - $48,824	1,700 Added 1.11%	154,700 $4.02 Million
Q3 2022 Nov 14, 2022	BUY	$24.1 - $39.66 $110,860 - $182,435	4,600 Added 3.1%	153,000 $4.37 Million
Q2 2022 Aug 15, 2022	BUY	$18.36 - $60.07 $2.72 Million - $8.91 Million	148,400 New	148,400 $3.65 Million
Q1 2022 May 16, 2022	SELL	$48.97 - $65.46 $1.66 Million - $2.23 Million	-34,000 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$53.3 - $75.84 $170,560 - $242,688	3,200 Added 10.39%	34,000 $2.11 Million
Q3 2021 Nov 15, 2021	BUY	$62.66 - $88.26 $1.6 Million - $2.25 Million	25,500 Added 481.13%	30,800 $1.95 Million
Q2 2021 Aug 16, 2021	SELL	$67.45 - $85.63 $600,305 - $762,107	-8,900 Reduced 62.68%	5,300 $437,000
Q1 2021 May 17, 2021	BUY	$65.1 - $93.59 $924,419 - $1.33 Million	14,200 New	14,200 $1.05 Million

Others Institutions Holding SWTX

# of Institutions

222

Shares Held

67.5M

Call Options Held

64.7K

Put Options Held

150K

View Full List

About SpringWorks Therapeutics, Inc.

Ticker SWTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,401,100
Market Cap $2.06B
Description
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also deve...

More about SWTX

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account